Boehringer Ingelheim has launched the Combivent Respimat ipratropium bromide/albuterol soft mist inhaler for the treatment of COPD in the United States. The Combivent Respimat includes enough doses for 30 days, compared to the Combivent MDI, which provides only enough medication for 25 days of treatment. The Combivent MDI, which uses a CFC propellant, will be available until July 2013.
BI VP of Clinical Development and Medical Affairs, Respiratory, Tunde Otulana commented, “Combivent Respimat is a testament to our company’s commitment to developing advancements for people living with respiratory disease. We are continuing to examine the potential of several late-stage investigational compounds also delivered by the Respimat inhaler.”
Read the Boehringer Ingelheim press release.
